CETRAXAL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CETRAXAL (CETRAXAL).
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to inhibition of DNA replication and transcription.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine. |
| Excretion | CETRAXAL is excreted primarily unchanged by the kidneys via glomerular filtration and tubular secretion. Approximately 70% of the dose is recovered in urine within 24 hours, with an additional 15% recovered in feces via biliary excretion, totaling ~85% elimination. The remainder is metabolized hepatically to inactive metabolites. |
| Half-life | The terminal elimination half-life is approximately 2.5–3.0 hours in patients with normal renal function (creatinine clearance >80 mL/min). This short half-life supports twice-daily dosing for most indications. In renal impairment (CrCl 20–50 mL/min), half-life extends to 6–9 hours, requiring dose adjustment. |
| Protein binding | CETRAXAL is approximately 98–99% bound to plasma proteins, primarily to albumin. The high protein binding limits distribution and prolongs half-life; only the unbound fraction (1–2%) is pharmacologically active. |
| Volume of Distribution | The apparent volume of distribution (Vd) is approximately 0.15–0.20 L/kg, indicating limited extravascular distribution (mainly in extracellular fluid). This low Vd reflects high protein binding and poor tissue penetration, except in inflamed tissues where distribution may increase modestly. |
| Bioavailability | Oral: Absolute bioavailability is approximately 85–90% due to first-pass metabolism (10–15% extraction). IV: 100%. Topical otic: Systemic bioavailability is negligible (<1%) due to minimal absorption through intact tympanic membrane; however, absorption may increase if the membrane is perforated. |
| Onset of Action | Oral: Onset of clinical effect (pain relief, fever reduction) occurs within 30–60 minutes after oral administration. Intravenous: Onset within 5–10 minutes after IV bolus. Topical (otic solution): Onset of local anesthetic effect within 2–5 minutes after instillation in the ear. |
| Duration of Action | Oral/IV: Duration of analgesic and antipyretic effect is approximately 4–6 hours, corresponding to the dosing interval. Topical otic: Duration of local anesthesia is 15–30 minutes, with antimicrobial effect persisting for 6–8 hours due to sustained drug levels in ear canal. |
| Molecular Weight | 500.57 Da |
1-2 drops in affected ear(s) twice daily for 7 days; otic solution.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for any degree of hepatic impairment. |
| Pediatric use | Children 6 months and older: 1-2 drops in affected ear(s) twice daily for 7 days; otic solution. |
| Geriatric use | No specific dose adjustment; use same dosing as adults with caution for impaired hepatic/renal function. |
| 1st trimester | There are no adequate and well-controlled studies in pregnant women. Animal studies have not revealed evidence of teratogenicity. Use only if clearly needed. |
| 2nd trimester | Corticosteroids are not recommended during pregnancy unless the potential benefit justifies the potential risk to the fetus. There is a risk of intrauterine growth retardation with prolonged systemic use. |
| 3rd trimester | Use with caution near term; systemic corticosteroids may cross the placenta and cause neonatal adrenal suppression. |
Clinical note
Comprehensive clinical and safety monograph for CETRAXAL (CETRAXAL).
| Placental transfer | Corticosteroids cross the placenta. The degree of transfer varies with the specific agent; fluticasone propionate has low systemic bioavailability and limited placental transfer. |
| Breastfeeding | Topical corticosteroids are unlikely to appear in breast milk in clinically significant amounts if used on small areas for short periods. However, caution should be exercised when applied to large areas or under occlusive dressings. |
■ FDA Black Box Warning
Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture in all ages; avoid with concomitant corticosteroids.
| Serious Effects |
Hypersensitivity to fluticasone propionate or any excipient in the formulationUntreated bacterial, fungal, or viral infections at the application site
| Precautions | Avoid prolonged use; may result in overgrowth of non-susceptible organisms including fungi. Discontinue if sensitization or severe irritation occurs. |
| Food/Dietary | No significant food interactions with otic ciprofloxacin. Systemic absorption minimal, so no dietary restrictions necessary. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | CETRAXAL (cetirizine) is an antihistamine classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but adequate and well-controlled human studies in pregnant women are lacking. Based on available data, first-trimester use is not associated with a major increase in congenital anomalies. Second- and third-trimester use is considered low risk. However, caution is advised, and use only if clearly needed. |
| Fetal Monitoring | No specific maternal-fetal monitoring is required beyond routine prenatal care. Observe for maternal adverse effects such as sedation, dizziness, or dry mouth. In neonates, especially with third-trimester exposure, monitor for potential withdrawal symptoms or paradoxical excitation. |
| Fertility Effects | CETRAXAL (cetirizine) is not known to have significant effects on fertility in humans. Animal studies showed no impairment at doses up to 25 times the clinical dose. Case reports are lacking; theoretical risk is minimal. |
| CETRAXAL (ciprofloxacin otic) is approved for acute otitis externa and acute otitis media with tympanostomy tubes. Use for 7 days. Avoid in patients with known hypersensitivity to quinolones. Not for systemic use. May cause local irritation. Assess tympanic membrane integrity before use. |
| Patient Advice | Warm the bottle in hands for 1-2 minutes before use to avoid dizziness. · Instill prescribed number of drops into the affected ear while lying down with ear facing up. · Remain lying down for 5 minutes after instillation to allow penetration. · Do not touch the dropper tip to ears or surfaces to avoid contamination. · Complete full course even if symptoms improve. · Report worsening pain, rash, or signs of allergy immediately. · Avoid swimming or water exposure until infection resolves. |